Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis

Lancet

Volumn 350, Issue 9086, 1997, Pages 1205-1209

  Joensuu, Jaana ^a   Koskenniemi, Eeva ^b   Pang, Xiao Li ^a   Vesikari, Timo ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; ROTAVIRUS VACCINE; SIMIAN ROTAVIRUS VACCINE; VIRUS VACCINE;

ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FINLAND; FOLLOW UP; GASTROENTERITIS; HUMAN; IMMUNIZATION; INCIDENCE; INFANT; INFANTILE DIARRHEA; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TIME; VIROLOGY; VIRUS INFECTION;

DIARRHEA, INFANTILE; DOUBLE-BLIND METHOD; FINLAND; FOLLOW-UP STUDIES; GASTROENTERITIS; HUMANS; IMMUNIZATION SCHEDULE; INCIDENCE; INFANT; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; TIME FACTORS; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 0031586446     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)05118-0     Document Type: Article

References (34)

1. Bern C, Martines J, de Zoysa I, Glass RI. The magnitude of the global problem of diarrhoeal disease: a ten year update. Bull World Health Organ 1992; 70: 705-14.
2. Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis 1996; 174 (suppl 1): S5-11.
3. Ryan MJ, Ramsay M, Brown D, Gay NJ, Farrington CP, Wall PG. Hospital admissions attributable to rotavirus infection in England and Wales. J Infect Dis 1996; 174 (suppl 1): S12-18.
4. Vesikari T, Isolauri E, D'Hondt E, Delem A, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984; i: 977-81.
5. Vesikari T, Isolauri E, Delem A, André FE. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before rotavirus epidemic. J Pediatr 1985; 107: 189-94.
6. Vesikari T, Ruuska T, Delem A, André FE, Beards GM, Flewett TH. Efficacy of two doses of RIT 4237 bovine rotavirus vaccine (at birth and 7 months of age) for prevention of rotavirus diarrhoea. Acta Paediatr Scand 1991; 80: 173-80.
7. Hanlon P, Hanlon L, Marsh V, et al. A trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian children. Lancet 1987; ii: 1342-45.
8. Lanata CF, Black RE, del Aguila R, et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 1989; 159: 452-59.
9. Clark HF, Borian FE, Bell LM, Modesto K, Gouvea V, Plotkin SA. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 1988; 158: 570-87.
10. Georges-Courbot MC, Monges J, Siopathis MR, et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 1991; 142: 405-11.
11. Kapikian AZ, Flores J, Hoshino Y, et al. Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a 'Jennerian' approach to vaccination. J Infect Dis 1986; 153: 815-22.
12. Vesikari T, Kapikian AZ, Delem A, Zissis G. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J Infect Dis 1986; 153: 832-39.
13. Flores J, Perez-Schael I, Gonzales M, et al. Protection against severe rotavirus diarrhea by rhesus rotavirus vaccine in Venezuelan infants. Lancet 1987; i: 882-84.
14. Christy C, Madore P, Pichichero M, et al. Field trial of rhesus rotavirus vaccine in infants. Pediatr Infect Dis J 1988; 7: 645-50.
15. Gothefors L, Wadell G, Juto P, Taniguchi K, Kapikian AZ, Glass RI. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. J Infect Dis 1989; 159: 753-57.
16. Rennels M, Losonsky G, Young A, et al. An efficacy trial of the rhesus rotavirus vaccine in Maryland. Am J Dis Child 1990; 144: 601-04.
17. Vesikari T, Rautanen T, Varis T, Beards GM, Kapikian AZ. Rhesus rotavirus candidate vaccine: clinical trial in children vaccinated between 2 and 5 months of age. Am J Dis Child 1990; 144: 285-89.
18. Madore HP, Christy C, Pichichero M, et al. Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. J Infect Dis 1992; 166: 235-43.
19. Midthun K, Greenberg HB, Hoshino Y, Kapikian AZ, Wyatt RG, Chanock RM. Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol 1985; 53: 949-54.
20. Vesikari T, Ruuska T, Green KY, Flores J, Kapikian AZ. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity. Pediatr Infect Dis J 1992; 11: 535-42.
21. Flores J, Perez-Schael I, Blanco M, et al. Reactogenicity and immunogenicity of a high titer rhesus rotavirus-based quadrivalent rotavirus vaccine. J Clin Microbiol 1993; 31: 2439-45.
22. Kapikian AZ, Hoshino Y, Chanock RM, Pérez-Schael I. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 1996; 174 (suppl 1): S65-72.
23. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA, for the US Rotavirus Vaccine Efficacy Group. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995; 273: 1191-96.
24. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. Pediatrics 1996; 97: 7-13.
25. Gouvea V, Glass RI, Woods P, et al. Polymerase chain reaction amplification and typing of rotavirus nucleic acids from stool specimens. J Clin Microbiol 1990; 28: 276-82.
26. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. Improved immunogenicity of oral DxRRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 1995; 13: 310-12.
27. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical diarrhoeal episodes. Scand J Infect Dis 1990; 22: 259-67.
28. Ward RL, Bernstein EI. Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. US Rotavirus Vaccine Efficacy Group. Vaccine 1995; 13: 1226-32.
29. Ward RL. Mechanism of protection against rotavirus in humans and mice. J Infect Dis 1996; 174 (suppl 1): S51-58.
30. Vesikari T, Joensuu J. Review of rotavirus vaccine trials in Finland. J Infect Dis 1996; 174 (suppl 1): S81-87.
31. Maunula L, v Bomsdorff C-H. Rotavirus serotypes and electropherotypes in Finland 1986 to 1990. Arch Virol 1995; 140: 877-90.
32. Lanata CF, Midthun K, Black RE, et al. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996; 174: 268-75.
33. Linhares AC, Gabbay YB, de Freitas RB, et al. Immunogenicity, safety and efficacy of rhesus-human reassortant rotavirus (RRV-tetravalent) vaccine in Belém, Brazil. Bull World Health Organ 1996; 74: 491-500.
34. Ruuska T, Vesikari T, Delem A, André FE, Beards GM, Flewett TH. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period. Scand J Infect Dis 1990; 22: 269-78.